Carl Icahn news from FierceBiotech
News
Enzon spins off biotech ops into $150M enterprise
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
Biogen squares off against Icahn in board battle
The war between Biogen Idec and Wall Street raider Carl Icahn is heating up. The Boston-based biotech has Read more...
ALSO NOTED: FDA approves Orencia; Delay on Amgen clotting drug decision; Icahn files suit for Biogen Idec papers; and much more
> The FDA has approved Bristol-Myers Squibb's Orencia for juvenile arthritis. Read more...
Icahn sells Genzyme stock
Carl Icahn has cashed in his Genzyme chips and evidently gone looking for another game. After arousing intense speculation last year that he would pull an Icahn and shake up Genzyme with big demands Read more...
ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...
> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a Read more...
Icahn aims for Biogen control
Carl Icahn says that Biogen Idec essentially ran a sham when it put itself up for auction Read more...
Genzyme wins Isis pact with $1.9B bid
Shares of Isis Pharmaceuticals rocketed up 45 percent after the biotech announced that Genzyme had signed on as a partner to Read more...
Biogen shares deflate as it gives up on sale
After ratcheting up expectations of a takeover and a hefty premium for stockholders, Biogen Idec pulled the rug out from Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight